NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

NCT01609023

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Rituximab

Countries: Greece

This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic lymphocytic leukemia. Data will be collected from eligible participants receiving rituximab according to the Summary of Product Characteristics (SPC) during 6 months of treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

\- Participants with CD20-positive B-cell chronic lymphocytic leukemia eligible for first-line or second-line therapy according to the approved SPC

Exclusion Criteria:

\- Contraindications to rituximab therapy according to the approved SPC

Locations (9)

Alexandroupoli, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Heraklion, Greece
Larissa, Greece
Pátrai, Greece
Pátrai, Greece
Thessaloniki, Greece